Diagnostic pitfalls in digestive neuroendocrine tumours

Area of Science:

• Oncology
• Medical Diagnostics
• Endocrinology

Background:

• Gastro-entero-pancreatic neuroendocrine tumors (GEP NET) are rare, heterogeneous, and often present with vague symptoms, causing diagnostic delays.
• Misinterpretation of diagnostic tests can lead to unnecessary investigations or missed diagnoses.

Purpose of the Study:

• To review common false positive and false negative cases in GEP NET diagnosis.
• To provide guidance on recognizing and managing diagnostic challenges in GEP NET.
• To critically evaluate the utility of specific diagnostic markers and imaging.

Main Methods:

• Review of clinical cases and diagnostic test performance for GEP NET.
• Analysis of the diagnostic value of chromogranin-A (serum marker) and Somatostatin receptor scintigraphy (imaging).
• Evaluation of hormone levels (e.g., gastrin) and urinary 5-hydroxy-indolic acetic acid (5-HIAA) in GEP NET diagnosis.

Main Results:

• Chromogranin-A and urinary 5-HIAA are frequently tested but can lead to false diagnoses if not interpreted within the clinical context.
• Certain tests, like 5-HIAA, are often negative and provide little information in specific GEP NET subtypes (e.g., pancreatic, rectal).
• Somatostatin receptor scintigraphy is a valuable imaging tool, but its high cost and reimbursement issues necessitate careful patient selection based on its known sensitivity and specificity.

Conclusions:

• Accurate diagnosis of GEP NET requires careful clinical correlation alongside diagnostic testing.
• Understanding the limitations and appropriate application of markers like chromogranin-A and 5-HIAA is crucial.
• Judicious use of imaging, such as Somatostatin receptor scintigraphy, is essential for effective GEP NET management.